Table 1.
Baseline characteristics of the calcitriol and placebo intervention groups
| variable | Placebo group(n = 64) | Calcitriol group(n = 64) | p-value |
|---|---|---|---|
| Body weight, kg | 83.3 ± 11.7 | 83.6 ± 13.1 | 0.88 |
| BMI, kg/m2 | 29.3 ± 3.8 | 29.0 ± 4.7 | 0.67 |
| WC, cm | 101.8 ± 10.8 | 100.5 ± 8.8 | 0.44 |
| HC, cm | 107.2 ± 7.7 | 106.8 ± 9.2 | 0.78 |
| FBS, mg/dl | 94.2 ± 23.0 | 98.1 ± 38.3 | 0.49 |
| Insulin, μIU/ml | 10.8 ± 5.5 | 9.6 ± 4.8 | 0.17 |
| Homa-IR | 2.1 ± 0.9 | 2.0 ± 0.8 | 0.43 |
| Quicki | 0.33 ± 0.03 | 0.34 ± 0.03 | 0.54 |
| HS Index | 41.4 ± 5.8 | 41.4 ± 5.6 | 0.95 |
| APRI index (IQR) | 0.30 (0.22–0.38) | 0.28 (0.23–0.37) | 0.16 |
| TC, mg/dl | 188.0 ± 60.9 | 187.8 ± 46.5 | 0.98 |
| TG (IQR),mg/dl | 168.0 (121.5–210.5) | 170.0 (134.0–236.0) | 0.32 |
| HDL cholesterol, mg/dl | 41.4 ± 11.2 | 38.3 ± 7.9 | 0.07 |
| LDL cholesterol, mg/dl | 97.9 ± 27.5 | 96.6 ± 25.9 | 0.77 |
| AST,IU | 29.2 ± 15.6 | 27.1 ± 8.7 | 0.35 |
| ALT (IQR), IU | 45.5 (32.8–57.0) | 23.0 (33.5–51.0) | 0.53 |
| GGT, IU | 35.2 ± 17.8 | 37.2 ± 21.7 | 0.57 |
| ALK, IU | 200.2 ± 52.6 | 197.3 ± 54.9 | 0.76 |
| Vitamin D, ng/ml | 17.5 ± 7.7 | 19.1 ± 9.6 | 0.29 |
| Hs-CRP (IQR), μg/ml | 2.9 (1.1–5.5) | 2.2 (1.1–4.8) | 0.99 |
| Leptin (IQR), ng/ml | 11.6 (6.6–19.7) | 9.9 (5.5–22.5) | 0.30 |
| Adiponectin (IQR), μg/ml | 18.6 (13.6–28.2) | 18.0 (10.8–24.4) | 0.89 |
Values are expressed as the mean ± SD or median (IQR). IQR interquartile range, BMI Body mass index, WC Waist circumference, HC Hip circumference, FBS Fasting blood glucose, Homa-IR Homeostatic Model Assessment for Insulin Resistance, HS index Hepatic steatosis index, APRI AST to Platelet Ratio Index, TC total cholesterol, TG Triglyceride, HDL-c High-density lipoproteins- cholesterol, LDL-c Low density lipoprotein- cholesterol, AST aspartate aminotransferase, ALT Alanine aminotransferase, GGT Gamma-glutamyl transferase, ALK Alkaline phosphatase, Hs-CRP High-sensitivity C-reactive protein